Ovid Therapeutics Inc Stock News

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by epilepsies and rare neurological disorders, today announced that management will participate virtually in the “Orphan Neuro and Neuromuscular” panel discussion at the Cowen 42 nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

– Ovid to License Gaboxadol to Healx –

Zacks Investment Research cut shares of Ovid Therapeutics (NASDAQ:OVID) from a buy rating to a hold rating in a report released on Tuesday morning, Zacks.com reports. According to Zacks, Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The companys product pipeline consists of OV101, is []

Ovid Therapeutics (NASDAQ:OVID) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. The firm currently has a $3.75 price target on the stock. Zacks Investment Researchs price target indicates a potential upside of 15.03% from the companys previous close. According to Zacks, []

Ovid Therapeutics Inc. (NASDAQ:OVID) has been assigned a consensus recommendation of Hold from the six brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year target price among analysts that have updated []

Zacks Investment Research upgraded shares of Ovid Therapeutics (NASDAQ:OVID) from a hold rating to a buy rating in a research report released on Thursday, Zacks.com reports. They currently have $3.75 price target on the stock. According to Zacks, Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological [] The post Ovid Therapeutics (NASDAQ:OVID) Raised to Buy at Zacks Investment Research appeared first on ETF Daily News .

Zacks Investment Research upgraded shares of Ovid Therapeutics (NASDAQ:OVID) from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. Zacks Investment Research currently has $3.50 price target on the stock. According to Zacks, Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for []

Northern Trust Corp trimmed its stake in Ovid Therapeutics Inc. (NASDAQ:OVID) by 83.0% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 82,052 shares of the companys stock after selling 399,811 shares during the quarter. Northern Trust Corps holdings in Ovid Therapeutics were worth $321,000 as of its []

Ovid Therapeutics Inc. (NASDAQ:OVID) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 663,000 shares, a drop of 39.2% from the October 31st total of 1,090,000 shares. Based on an average trading volume of 242,700 shares, the days-to-cover ratio is []

Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) have been given a consensus rating of Hold by the nine research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among analysts []

Zacks Investment Research upgraded shares of Ovid Therapeutics (NASDAQ:OVID) from a hold rating to a buy rating in a research report report published on Thursday, Zacks.com reports. The firm currently has $4.00 target price on the stock. According to Zacks, Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with []

Vanguard Group Inc. boosted its holdings in shares of Ovid Therapeutics Inc. (NASDAQ:OVID) by 0.3% during the second quarter, Holdings Channel reports. The firm owned 3,505,637 shares of the companys stock after acquiring an additional 9,251 shares during the quarter. Vanguard Group Inc. owned approximately 0.05% of Ovid Therapeutics worth $13,706,000 at the end of []

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurologi

Dr. Michael Poole to Join the Board of Directors

There are promising results for OV-935 in patients with Dravet Syndrome, with questionable results in patients with Lennox-Gastaut Syndrome (LGS). Pipeline drug OV-935 shows high revenue potential.